

Interested in Joining ToxIC?

We invite all ACMT members to get involved with ToxIC. We welcome new research ideas, collaborations, and partnerships.

To join, please contact us at toxic@acmt.net.

Participating Site Benefits:

- Explore the Core Registry for pilot data and to generate research hypotheses.
- Utilize medical toxicologist generated data streams for publications.
- Track cases by fellow/attending, and type of case, and perform internal quality assurance projects.
- Participate as a site investigator in NIH, FDA, and CDC funded multicenter research and surveillance studies.
- Network with other investigators.



toxicregistry.org | @ToxicACMT
American College of
Medical Toxicology
10645 N. Tatum Blvd.,
Suite 200-111
Phoenix, AZ 85028
Phone: (844) 226-8333
Email: toxic@acmt.net



ToxIC

Toxicology
Investigators
Consortium

**ToxIC is a
multicenter network
for toxicosurveillance
and research in
medical toxicology**

toxicregistry.org

About Us

Who We Are

The Toxicology Investigators Consortium (Toxic) is a multicenter network for toxicosurveillance and research in medical toxicology. Founded in 2010, Toxic is the major research program of the American College of Medical Toxicology (ACMT).

Structure and Organization

Toxic leadership and key staff include medical toxicology physicians, PhD research scientists and epidemiologists, and masters-level scientists who direct the program and manage its data coordination center. Toxic sites represent academic and community medical centers across the country. Each site's participation is under the direction of a medical toxicologist.

Our Goals

The goal of this network is to empower medical toxicology investigators across the US and internationally to conduct impactful and rigorous multicenter toxicosurveillance and research into the prevention and management of toxicological disorders in adults and children.

Funding and Collaborations

Toxic currently receives funding from the FDA, CDC, NIH, SAMHSA, and industry partners.

Projects

Core Registry

The Core Registry was the first ever registry of patients cared for by medical toxicologists. Initiated in 2010 with over 30 participating sites, the registry has grown to over 100,000 cases. All cases represent a patient that has been formally evaluated by a medical toxicology physician.

North American Snakebite Registry (NASBR)

Since 2013, the nationwide NASBR project prospectively gathers information from medical toxicologists providing care for patients with snake envenomations. The NASBR has had over 2,300 cases of snakebite.

Toxic Novel Opioid and Stimulant Exposures (NOSE)

The NOSE project, supported by Substance Abuse and Mental Health Services Administration (SAMHSA) as part of the Opioid Response Network, identifies and reports on cases with a novel opioid and/or psychostimulant exposure. Emerging trends are reviewed and published in brief reports that are disseminated nationally to public health partners.

Natural Toxins Registry: Plants and Mushrooms

This registry contains detailed information on the clinical course of patients who ingest poisonous plants and mushrooms.

Fentanyl Analog Study (Fentalog)

This NIH funded project initiated in 2020 to study the fentanyl epidemic at 10 sites across the US. Detailed clinical information on suspected opioid overdoses is obtained and biological samples are collected for comprehensive drug molecular identification performed by the Center for Forensic Sciences, Research and Education (CFSRE).

Drug Overdose Toxicosurveillance Reporting Program (DOTS)

The FDA-funded DOTS program investigated severe and life-threatening opioid and stimulant overdoses through detailed clinical information, structured patient interviews, and comprehensive laboratory testing.

Real-World Examination of Naloxone for Drug Overdose Reversal (RENDOR)

This project examines the real-world administration of naloxone by bystanders, community members, fire and police departments, and emergency medical services (EMS) personnel.

Opioid Use Disorder (OUD) Project

This subregistry, funded by the CDC, collects de-identified data on OUD treatment and harm reduction measures.